x****6
发帖数: 4339 | 1 生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站台
，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦副
辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
如此奇葩，请业内人士点评背后的sense！
http://www.wsj.com/articles/theranos-is-subject-of-criminal-pro |
a***y
发帖数: 19743 | 2 CEO不懂science真可怕
【在 x****6 的大作中提到】
: 生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站台
: ，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦副
: 辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
: 如此奇葩，请业内人士点评背后的sense！
: http://www.wsj.com/articles/theranos-is-subject-of-criminal-pro
|
l****y
发帖数: 398 | 3 这与现在推崇的think big, think different 的文化有关，
妹子选错了行当，不应该选一个highly regulated 的
[在 xiao86 (xiao86) 的大作中提到：]
:生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站
台，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦
副辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
:如此奇葩，请业内人士点评背后的sense！
:http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055 |
x****6
发帖数: 4339 | 4 我也觉得：她要是当初去了IT行业，按照她这个召集资源的能力，绝对已经是知名企业
家了。
【在 l****y 的大作中提到】
: 这与现在推崇的think big, think different 的文化有关，
: 妹子选错了行当，不应该选一个highly regulated 的
: [在 xiao86 (xiao86) 的大作中提到：]
: :生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站
: 台，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦
: 副辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
: :如此奇葩，请业内人士点评背后的sense！
: :http://www.wsj.com/articles/theranos-is-subject-of-criminal-probe-by-u-s-1461019055
|
y******m
发帖数: 143 | 5 美国的创新文化下产生的怪物。有的时候风险喜欢些奇巧怪的东西，但是风险评估的时
候，没有找到专业的团队进行评估。另外小姑娘的教育家庭也符合美国造神运动的标准
。呆久了，其实可以发现很多所谓的教授，基础知识相当的不扎实！ |
s******r
发帖数: 1245 | 6 美国能做大的公司都是这么出来的，只不过这家太极端了，经营团队的能力超出技术部
门太多，以致于吹出来的泡泡填不上，绝对是做技术的猥琐男拖了后腿。再次论证了选
对行业的重要性。
【在 x****6 的大作中提到】
: 生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站台
: ，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦副
: 辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
: 如此奇葩，请业内人士点评背后的sense！
: http://www.wsj.com/articles/theranos-is-subject-of-criminal-pro
|
x****6
发帖数: 4339 | 7 生计行业还是做技术的出来创业比较好。
【在 s******r 的大作中提到】
: 美国能做大的公司都是这么出来的，只不过这家太极端了，经营团队的能力超出技术部
: 门太多，以致于吹出来的泡泡填不上，绝对是做技术的猥琐男拖了后腿。再次论证了选
: 对行业的重要性。
|
l******n
发帖数: 298 | 8 销售，政治，商业，尤其是股市，金融。很多时候都是大骗子干的事情。生物医药涉及
到人命，往往有特殊要求。
我早就说了，股市放假消息，还有赌球赌彩这些越能骗越好。但是生物就不行啊。 |
C***H
发帖数: 508 | 9 这个本来就是世家子弟诓钱的公司吧，至少我知道的业内人士都躲得远远的。只不过不
小心泡泡吹太大了收不了场而已。
【在 x****6 的大作中提到】
: 生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站台
: ，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦副
: 辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
: 如此奇葩，请业内人士点评背后的sense！
: http://www.wsj.com/articles/theranos-is-subject-of-criminal-pro
|
x****6
发帖数: 4339 | 10 如果早就知道实情，那为什么没有业内人士出来揭穿呢?!
比如我不是这个行业的，我对这个行业的了解竟然主要的来自于这个公司对医学诊断的
宣传，包括这个妹子在TED上的激情演讲。另外还有Whitesides的一些工作。看着骗子
占领公共话语空间，浪费纳税人的钱，这些业内人士也太坐得住了！
看来，美帝也需要方舟子。
【在 C***H 的大作中提到】
: 这个本来就是世家子弟诓钱的公司吧，至少我知道的业内人士都躲得远远的。只不过不
: 小心泡泡吹太大了收不了场而已。
|
|
|
w*********o
发帖数: 3030 | 11 Come on, why the owner of this website couldn't just give up the idea of
robots already? |
x****6
发帖数: 4339 | 12 谁特妈回到生物版来放机器文。
【在 w*********o 的大作中提到】
: Come on, why the owner of this website couldn't just give up the idea of
: robots already?
|
u***n
发帖数: 10554 | |
x****6
发帖数: 4339 | 14 这个我倒是不认为。毕竟事情的核心是她的产品没有通过医院的验证；要真是通过了，
投资的收益将是几十倍到几百倍这个量级。
前面有人说得很好：她的公关管理团队和技术团队严重脱节。
【在 u***n 的大作中提到】
: 难道不是资本抛弃了她？
|
s***y
发帖数: 198 | 15 她是非常优秀的CEO。等放出来了，可以去YAHOO当CEO。
【在 x****6 的大作中提到】
: 这个我倒是不认为。毕竟事情的核心是她的产品没有通过医院的验证；要真是通过了，
: 投资的收益将是几十倍到几百倍这个量级。
: 前面有人说得很好：她的公关管理团队和技术团队严重脱节。
|
G*******i
发帖数: 32 | 16 看不了WSJ，哪个大神给贴个原文？
【在 x****6 的大作中提到】
: 生物诊断的明日之星，公司成立13年，获得90亿美元的风投，引明星、政治家为其站台
: ，结果在产品上市前夕才发现，它是一个骗局。而这个旋风的核心是一个19岁在斯坦副
: 辍学创业的妹子。这个故事足够拍一部《生物硅谷之狼》的电影了。
: 如此奇葩，请业内人士点评背后的sense！
: http://www.wsj.com/articles/theranos-is-subject-of-criminal-pro
|
w*********o
发帖数: 3030 | 17 Robots who have no mother.
【在 x****6 的大作中提到】
: 谁特妈回到生物版来放机器文。
|
x****6
发帖数: 4339 | 18 By Christopher Weaver,
John Carreyrou and
Michael Siconolfi
April 18, 2016 6:37 p.m. ET
296 COMMENTS
Federal prosecutors have launched a criminal investigation into whether
Theranos Inc. misled investors about the state of its technology and
operations, according to people familiar with the matter.
Walgreens Boots Alliance Inc. and the New York State Department of Health
have received subpoenas in recent weeks seeking documents and testimony
about representations made to them by the Palo Alto, Calif., blood-testing
company, some of the people said.
Walgreens has been Theranos’s main conduit to consumers since the companies
announced a partnership in 2013 that now includes 40 Theranos wellness
centers at drugstores in Arizona. The New York agency received an
application from Theranos for a laboratory license in the state.
People familiar with the matter said the subpoenas seek broad information
about how Theranos described its technologies and the progress it was making
developing those technologies.
Investigators are also examining whether Theranos misled government
officials, which can be a crime under federal law, some of the people said.
Such subpoenas don’t necessarily mean prosecutors are actively seeking an
indictment. People familiar with the matter said the investigation is at an
early stage.
In addition to the criminal probe, the Securities and Exchange Commission is
examining whether Theranos made deceptive statements to investors when it
solicited funding, according to people familiar with the matter. Theranos
was valued at $9 billion in a funding round in 2014 and the majority stake
of Elizabeth Holmes, the startup’s founder and chief executive, at more
than half that.
In a statement, Theranos said: “The company continues to work closely with
regulators and is cooperating fully with all investigations.”
SEC spokeswoman Judith Burns declined to comment, as did Justice Department
spokesman Peter Carr and Abraham Simmons, an assistant U.S. attorney in San
Francisco, where the federal investigation is being conducted.
Walgreens spokesman Michael Polzin also declined to comment. New York health
-department spokesman J.P. O’Hare didn’t respond to requests for comment.
Since launching Theranos in 2003, Ms. Holmes has set out to revolutionize
the blood-testing industry. Before the company made changes to its website
earlier this year, the website cited “breakthrough advancements” that made
it possible to run “the full range” of lab tests on a few drops of blood
pricked from a finger.
In October, The Wall Street Journal reported that Theranos did the vast
majority of more than 200 tests it offered to consumers on traditional lab
machines purchased from other companies. The Journal also reported that some
former employees doubted the accuracy of a small number of tests run on the
devices Theranos invented, code-named Edison.
Theranos has declined to say how many tests or which ones it runs on
commercial machines. The company has said its technology has the capability
to handle a broad range of tests.
Federal officials began requesting information about Theranos in January and
February, according to the people familiar with the matter. Those informal
requests were followed by grand-jury subpoenas from a federal court in San
Francisco in March, the people said. Agents from the Federal Bureau of
Investigation and U.S. Postal Inspection Service are assisting in the
investigation, the people said.
The news release issued when the Walgreens deal was announced said consumers
“will be able to access less invasive and more affordable clinician-
directed lab testing, from a blood sample as small as a few drops, or 1/1,
000 the size of a typical blood draw.”
As part of the deal, Walgreens has invested at least $50 million into
Theranos, according to people familiar with the matter.
In January, though, Walgreens notified Theranos that it intends to terminate
the partnership unless the company quickly fixes problems found in a
federal inspection completed in November at Theranos’s lab in Newark, Calif.
Last month, federal health regulators proposed banning Ms. Holmes from the
blood-testing business for at least two years after concluding that the
company failed to resolve what officials have called major problems found
during the inspection.
Theranos spokeswoman Brooke Buchanan said the company has submitted a
response addressing the concerns and hopes to avert the sanctions. The
sanctions haven’t been imposed. If they are, Theranos can appeal.
The company began running some tests on Edisons in its California lab in
late 2013, according to some former employees and the federal inspection
report.
Theranos’s lab-license application in New York said the company planned to
test patients’ blood on traditional lab machines and didn’t mention any
proprietary testing devices, said someone with knowledge of the application.
Theranos also enrolled in the New York agency’s proficiency-testing program
, in which regulators monitor a lab’s accuracy by sending it samples of
preserved blood with known characteristics and asking the lab to test them.
If the lab’s results are in line with those reported by a peer group, it
receives a passing grade.
In March 2014, a Theranos employee alleged to the agency in an email that
Theranos was manipulating its proficiency-testing program by reporting back
results obtained from traditional lab machines for some tests, instead of
the Edison devices with which it was running those tests on live patient
samples.
Theranos said it uses an alternative process for proficiency testing. The
process “has been disclosed to and discussed with regulators,” said Ms.
Buchanan, the Theranos spokeswoman. “Theranos’ proficiency testing process
meets the regulatory requirements.”
State records show Theranos never obtained a New York license. The person
with knowledge of the company’s application said it was shelved when
Theranos’s lab director at the time wrote to the agency to inform it he had
resigned and wanted his name taken off the application.
The SEC has been paying closer attention recently to ensuring that large
private technology firms properly inform investors about their finances and
valuations. In a speech at Stanford University late last month, SEC
Chairwoman Mary Jo White said: “The risk of distortion and inaccuracy is
amplified because start-up companies, even quite mature ones, often have far
less robust internal controls and governance procedures than most public
companies.”
—Jean Eaglesham contributed to this article.
【在 G*******i 的大作中提到】
: 看不了WSJ，哪个大神给贴个原文？
|
C***H
发帖数: 508 | 19 也没有真的知道实情，只是她的那些指标很不现实。但是一看她的board member就知道
惹不起。
[在 xiao86 (xiao86) 的大作中提到：]
:如果早就知道实情，那为什么没有业内人士出来揭穿呢?!
:比如我不是这个行业的，我对这个行业的了解竟然主要的来自于这个公司对医学诊断
的宣传，包括这个妹子在TED上的激情演讲。另外还有Whitesides的一些工作。看着骗子
:占领公共话语空间，浪费纳税人的钱，这些业内人士也太坐得住了！
:看来，美帝也需要方舟子。 |
w********i
发帖数: 76 | 20 这个也有老员工的爆料。
想一想，和“冯”事件也有共同之处： 都是内部人反水 |
|
|
g********0
发帖数: 6201 | 21 Holmes Holmes wacha gonna do, wacha gonna do when they come for you? |
S****x
发帖数: 317 | |
D*a
发帖数: 6830 | |
e*******o
发帖数: 4654 | 24 特意看了一下她的TEDtalk
50年后，可能她说愿景会实现，测试的范围也会远远扩大。
不过唯一不现实的就是，采血量。 很难压缩
【在 D*a 的大作中提到】
: 我当初听她TED就觉得不靠谱
|
D*a
发帖数: 6830 | 25 对，就是采血量的问题，而且静脉血和指尖血的成分占比并不完全一样。
说一种两种研发出来了低剂量准确测量我信，比如herpes，一下好几十种全研发出来了
，怎么可能。
前瞻性造假，哈哈
【在 e*******o 的大作中提到】
: 特意看了一下她的TEDtalk
: 50年后，可能她说愿景会实现，测试的范围也会远远扩大。
: 不过唯一不现实的就是，采血量。 很难压缩
|
s********e
发帖数: 239 | 26 米国确实特别喜欢造神
【在 y******m 的大作中提到】
: 美国的创新文化下产生的怪物。有的时候风险喜欢些奇巧怪的东西，但是风险评估的时
: 候，没有找到专业的团队进行评估。另外小姑娘的教育家庭也符合美国造神运动的标准
: 。呆久了，其实可以发现很多所谓的教授，基础知识相当的不扎实！
|
y******8
发帖数: 1764 | 27 也没什么奇葩吧。应该说希望这家公司成功的比希望它失败的要多。
但加起来也没有看热闹的多 |
I*****h
发帖数: 470 | 28 深有同感！！！！！
【在 a***y 的大作中提到】
: CEO不懂science真可怕
|
